Drug intelligence / Profile preview

ondansetron + ibuprofen + paracetamol

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of ondansetron (a serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting), ibuprofen (a non-steroidal anti-inflammatory drug), and paracetamol (also known as acetaminophen, a non-opioid analgesic and antipyretic). This combination would theoretically provide anti-emetic effects from ondansetron while delivering pain relief and fever reduction from both ibuprofen and paracetamol.

Other names: ondansetron, ibuprofen, paracetamolTOXIL-2 regimenTOXIL2 regimenTOXIL 2 regimen

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR3A (5-hydroxytryptamine receptor 3A)PGHS-1 (Prostaglandin G/H Synthase 1)COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)

Beyond the preview

Go deeper on ondansetron + ibuprofen + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ondansetron + ibuprofen + paracetamol.

Explore the full profile